276 related articles for article (PubMed ID: 32761407)
1. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
[TBL] [Abstract][Full Text] [Related]
2. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.
Geladaris A; Torke S; Saberi D; Alankus YB; Streit F; Zechel S; Stadelmann-Nessler C; Fischer A; Boschert U; Häusler D; Weber MS
Acta Neuropathol; 2024 Apr; 147(1):75. PubMed ID: 38656399
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
[TBL] [Abstract][Full Text] [Related]
4. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
[TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis.
Saberi D; Geladaris A; Dybowski S; Weber MS
Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L
J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis.
Torke S; Weber MS
Expert Opin Investig Drugs; 2020 Oct; 29(10):1143-1150. PubMed ID: 32772592
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
Keaney J; Gasser J; Gillet G; Scholz D; Kadiu I
J Neuroimmune Pharmacol; 2019 Sep; 14(3):448-461. PubMed ID: 30758770
[TBL] [Abstract][Full Text] [Related]
9. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
10. BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy.
Li R; Tang H; Burns JC; Hopkins BT; Le Coz C; Zhang B; de Barcelos IP; Romberg N; Goldstein AC; Banwell BL; Luning Prak ET; Mingueneau M; Bar-Or A
Acta Neuropathol; 2022 Apr; 143(4):505-521. PubMed ID: 35303161
[TBL] [Abstract][Full Text] [Related]
11. Imaging meningeal inflammation in CNS autoimmunity identifies a therapeutic role for BTK inhibition.
Bhargava P; Kim S; Reyes AA; Grenningloh R; Boschert U; Absinta M; Pardo C; Van Zijl P; Zhang J; Calabresi PA
Brain; 2021 Jun; 144(5):1396-1408. PubMed ID: 33724342
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
13. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Montalban X; Arnold DL; Weber MS; Staikov I; Piasecka-Stryczynska K; Willmer J; Martin EC; Dangond F; Syed S; Wolinsky JS;
N Engl J Med; 2019 Jun; 380(25):2406-2417. PubMed ID: 31075187
[TBL] [Abstract][Full Text] [Related]
14. Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib.
Rijvers L; van Langelaar J; Bogers L; Melief MJ; Koetzier SC; Blok KM; Wierenga-Wolf AF; de Vries HE; Rip J; Corneth OB; Hendriks RW; Grenningloh R; Boschert U; Smolders J; van Luijn MM
JCI Insight; 2022 Aug; 7(16):. PubMed ID: 35852869
[TBL] [Abstract][Full Text] [Related]
15. Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination.
Evonuk KS; Wang S; Mattie J; Cracchiolo CJ; Mager R; Ferenčić Ž; Sprague E; Carrier B; Schofield K; Martinez E; Stewart Z; Petrosino T; Johnson GA; Yusuf I; Plaisted W; Naiman Z; Delp T; Carter L; Marušić S
Acta Neuropathol Commun; 2023 Jul; 11(1):115. PubMed ID: 37438842
[TBL] [Abstract][Full Text] [Related]
16. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.
Nuesslein-Hildesheim B; Ferrero E; Schmid C; Huck C; Smith P; Tisserand S; Rubert J; Bornancin F; Eichlisberger D; Cenni B
J Neuroinflammation; 2023 Aug; 20(1):194. PubMed ID: 37633912
[TBL] [Abstract][Full Text] [Related]
17. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
Roman-Garcia S; Merino-Cortes SV; Gardeta SR; de Bruijn MJW; Hendriks RW; Carrasco YR
Front Immunol; 2018; 9():2027. PubMed ID: 30237801
[TBL] [Abstract][Full Text] [Related]
18. B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice.
Riccio LGC; Jeljeli M; Santulli P; Chouzenoux S; Doridot L; Nicco C; Reis FM; Abrão MS; Chapron C; Batteux F
Hum Reprod; 2019 Jul; 34(7):1225-1234. PubMed ID: 31247078
[TBL] [Abstract][Full Text] [Related]
19. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
[TBL] [Abstract][Full Text] [Related]
20. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
Carnero Contentti E; Correale J
Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]